StockData
ResMed Inc logo

ResMed Inc (RMD) KPIs and segments

RMDNYSESurgical & Medical Instruments & ApparatusFiscal year ends June 30Also trades as RSMDF
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 21/3014% below fair value
$242.61+4.76 (+2.00%)

Close on Nov 18, 2026Market cap $34.12BP/E 22.1Yield 0.99%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của ResMed · năm tài chính kết thúc June 30 (FY2026 ended June 30, 2026; Q1 FY2027 ended September 30, 2026)

Nhìn nhanh KPI của ResMed: 40 chỉ số vận hành, trong đó có Global Sleep & Breathing Health Revenue, Global Devices Revenue và Global Masks and Other Revenue, lấy từ 144 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Năm tài chính của ResMed kết thúc June 30 (FY2026 ended June 30, 2026; Q1 FY2027 ended September 30, 2026) — Q1 FY27 = CQ3 2026 (quý dương lịch).

Periods

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q1 FY27
Q4 FY26
Q3 FY26
Q2 FY26
Q1 FY26
Q4 FY25
Q3 FY25
Q2 FY25
Q1 FY25
Q4 FY24
Q3 FY24
Q2 FY24
Devices3
Global revenue($M)
736726680676669626638606
U.S., Canada and Latin America($M)
448448413423414385399371
Combined Europe, Asia and other markets($M)
288278267254255241239235
Residential Care Software($M)1
155172171167166167161156157152148145
Global revenue($M)
171167166161156157148145
Masks and other3
Global revenue($M)
525530489454456442411412
U.S., Canada and Latin America($M)
371387361327334323288298
Combined Europe, Asia and other markets($M)
154143128128122119123114
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2
Global revenue($M)
1,4311,4231,3361,2921,2821,2251,2231,1971,163
U.S., Canada and Latin America($M)
819835775749749707687669
Combined Europe, Asia and other markets($M)
442421395381377360362349
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)3
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)3
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)3
Global Sleep & Breathing Health Revenue ($M)($M)2
1,2601,2921,2611,2561,1691,1811,1311,1261,0681,0711,0491,018
Global Sleep & Breathing Health — Revenue Growth YoY (%)(%)
8.0%9.0%11.0%12.0%10.0%10.0%8.0%11.0%11.0%9.0%7.0%11.0%
Global Sleep & Breathing Health — Constant Currency Growth YoY (%)(%)
7.0%8.0%8.0%10.0%8.0%9.0%9.0%11.0%11.0%9.0%7.0%10.0%
Global Devices Revenue ($M)($M)5
720750736726680694676669626635638606
Global Devices — Revenue Growth YoY (%)(%)
6.0%8.0%9.0%9.0%9.0%9.0%6.0%10.0%11.0%5.0%5.0%12.0%
Global Devices — Constant Currency Growth YoY (%)(%)
6.0%7.0%6.0%7.0%7.0%8.0%7.0%11.0%10.0%6.0%5.0%11.0%
Global Devices — Share of Quarterly Consolidated Revenue (Legacy through FY2026Q3, %)(%)
51.0%51.0%51.0%52.0%52.0%52.0%51.0%52.0%53.0%52.0%
Americas Devices Revenue ($M)($M)3
436459448448413433423415385406399371
Americas Devices — Revenue Growth YoY (%)(%)
6.0%6.0%6.0%8.0%8.0%7.0%6.0%12.0%11.0%5.0%7.0%7.0%
Americas Sleep Devices Revenue ($M)($M)1
436452436438405
Americas Sleep Devices — Core Constant Currency Growth YoY (%)(%)
6.0%8.0%7.0%10.0%9.0%
Americas Life Support Devices Revenue ($M)($M)1
0711109
Americas Life Support Devices — Core Constant Currency Growth YoY (%)(%)
-94.0%-45.0%-29.0%-41.0%-27.0%
Rest of World Devices Revenue ($M)($M)4
284291288278267261254255241229239235
Rest of World Devices — Revenue Growth YoY (%)(%)
6.0%12.0%14.0%9.0%11.0%14.0%6.0%9.0%10.0%6.0%1.0%19.0%
Rest of World Devices — Constant Currency Growth YoY (%)(%)
6.0%9.0%6.0%5.0%7.0%10.0%9.0%9.0%9.0%8.0%1.0%16.0%
Rest of World Sleep Devices Revenue ($M)($M)1
280281276266250
Rest of World Sleep Devices — Core Constant Currency Growth YoY (%)(%)
13.0%13.0%9.0%6.0%6.0%
Rest of World Life Support Devices Revenue ($M)($M)1
310121217
Rest of World Life Support Devices — Core Constant Currency Growth YoY (%)(%)
-79.0%-38.0%-30.0%-15.0%9.0%
Global Masks and Other Revenue ($M)($M)5
540542525530489487454456442436411412
Global Masks and Other — Revenue Growth YoY (%)(%)
10.0%11.0%15.0%16.0%11.0%12.0%11.0%11.0%11.0%14.0%10.0%10.0%
Global Masks and Other — Constant Currency Growth YoY (%)(%)
10.0%10.0%12.0%14.0%10.0%11.0%12.0%11.0%11.0%15.0%10.0%9.0%
Global Masks and Other — Share of Quarterly Consolidated Revenue (Legacy through FY2026Q3, %)(%)
37.0%37.0%37.0%36.0%35.0%36.0%36.0%36.0%34.0%35.0%
Americas Masks and Other Revenue ($M)($M)1
397394371387361359327335323321288298
Americas Masks and Other — Revenue Growth YoY (%)(%)
10.0%10.0%14.0%16.0%12.0%12.0%13.0%12.0%10.0%17.0%12.0%10.0%
Rest of World Masks and Other Revenue ($M)($M)2
143148154143128128128122119115123114
Rest of World Masks and Other — Revenue Growth YoY (%)(%)
12.0%16.0%20.0%17.0%7.0%11.0%4.0%7.0%13.0%7.0%6.0%9.0%
Rest of World Masks and Other — Constant Currency Growth YoY (%)(%)
11.0%12.0%10.0%8.0%4.0%7.0%7.0%7.0%11.0%9.0%6.0%4.0%
Americas Sleep & Breathing Health Total Revenue ($M)($M)2
833853819835775792749749707727688669
Americas Sleep & Breathing Health — Revenue Growth YoY (%)(%)
8.0%8.0%9.0%11.0%10.0%9.0%9.0%12.0%11.0%10.0%9.0%9.0%
Americas Sleep & Breathing Health — Share of Quarterly Revenue (Legacy through FY2026Q3, %)(%)
57.0%59.0%58.0%58.0%58.0%59.0%58.0%60.0%57.0%57.0%
Rest of World Sleep & Breathing Health Total Revenue ($M)($M)3
426439442421395389381377360344362349
Rest of World Sleep & Breathing Health — Revenue Growth YoY (%)(%)
8.0%13.0%16.0%12.0%10.0%13.0%5.0%8.0%11.0%7.0%3.0%16.0%
Rest of World Sleep & Breathing Health — Constant Currency Growth YoY (%)(%)
8.0%10.0%7.0%6.0%6.0%9.0%8.0%8.0%10.0%8.0%3.0%12.0%
Rest of World Sleep & Breathing Health — Share of Quarterly Revenue (Legacy through FY2026Q3, %)(%)
31.0%29.0%30.0%30.0%29.0%29.0%29.0%28.0%30.0%30.0%
Residential Care Software (RCS) Revenue ($M)($M)3
155172171167166167161157157152148145
Residential Care Software — Revenue Growth YoY (%)(%)
-7.0%3.0%6.0%7.0%6.0%10.0%9.0%8.0%13.0%10.0%8.0%24.0%
Residential Care Software — Constant Currency Growth YoY (%)(%)
5.0%2.0%4.0%5.0%5.0%9.0%10.0%8.0%12.0%10.0%8.0%
Residential Care Software — Share of Quarterly Consolidated Revenue (Legacy through FY2026Q3, %)(%)
12.0%12.0%12.0%12.0%13.0%12.0%13.0%12.0%13.0%13.0%
Total Operating Segments Profit ($M)($M)
614582634622585575548538509484495451
Total Operating Segments Cost of Sales ($M)($M)2
528593530534504517515518498
Sleep & Breathing Health — Segment Cost of Sales ($M)($M)1
480542542483487468467468450428448461
Sleep & Breathing Health — Acquired Intangible Amortization in Cost of Sales (Legacy through FY2026Q4, $M)($M)
2.012.011.421.423.021.181.231.211.221.051.32
Residential Care Software — Segment Cost of Sales ($M)($M)1
48.260.460.457.357.948.548.349.848.346.54846.9
Residential Care Software — Acquired Intangible Amortization in Cost of Sales (Legacy through FY2026Q4, $M)($M)
6.296.296.396.406.346.266.406.466.776.766.93
Total Operating Segments Research & Development Expense ($M)($M)2
88.693.382.679.975.975.972.174.272.1
Sleep & Breathing Health — Segment R&D Expense ($M)($M)
65.966.756.454.150.951.147.250.147.9
Residential Care Software — Segment R&D Expense ($M)($M)
22.726.626.225.82524.724.924.124.2
Total Operating Segments SG&A Expense ($M)($M)2
185196185187171180156153146
Sleep & Breathing Health — Segment SG&A Expense ($M)($M)
155160150148135142122119109
Residential Care Software — Segment SG&A Expense ($M)($M)
29.835.835.639.536.338.434.733.736.6
Sleep & Breathing Health — Segment Depreciation & Amortization ($M)($M)2
26.82336.927.32539.522.825.22321.821.822
Sleep & Breathing Health — Segment Goodwill ($M)($M)1
1,0971,093899884884884758747769758745752
Non-GAAP Gross Margin (%)(%)3
62.5%62.3%62.8%62.3%62.0%61.4%59.9%59.2%59.2%59.1%58.5%56.9%
GAAP Gross Margin (%)(%)
61.5%58.8%62.2%61.8%61.5%60.8%59.3%58.6%58.6%58.5%57.9%55.6%
Non-GAAP Gross Profit ($M)($M)
884911899887829828774759725724701662
Non-GAAP Cost of Sales (Legacy through FY2026Q4, $M)($M)
552533536507520518523500500496501
Non-GAAP Income from Operations ($M)($M)3
506515525517482476445436406401394366
Non-GAAP Income from Operations — Growth YoY (%)(%)
5.0%8.0%18.0%19.0%19.0%19.0%13.0%19.0%27.0%30.0%23.0%20.0%
GAAP Income from Operations — Growth YoY (%)(%)
1.0%-1.0%17.0%18.0%15.0%19.0%14.0%52.0%34.0%38.0%25.0%-2.0%
Non-GAAP SG&A Expenses ($M)($M)6
276291280259265245
Non-GAAP Net Income ($M)($M)3
418428417412375375349358325306314277
Non-GAAP Net Income — Growth YoY (%)(%)
12.0%14.0%20.0%15.0%15.0%22.0%11.0%29.0%35.0%30.0%27.0%13.0%
GAAP Net Income — Growth YoY (%)(%)
20.0%1.0%9.0%14.0%12.0%30.0%21.0%65.0%42.0%27.0%29.0%-7.0%
Non-GAAP Diluted EPS ($)($)2
2.912.952.862.812.552.552.372.432.202.082.131.88
Non-GAAP Diluted EPS — Growth YoY (%)(%)
14.0%16.0%21.0%16.0%16.0%23.0%11.0%29.0%34.0%30.0%27.0%13.0%
GAAP Diluted EPS — Growth YoY (%)(%)
23.0%2.0%10.0%15.0%12.0%30.0%22.0%65.0%42.0%27.0%29.0%-7.0%
Free Cash Flow — Published Non-GAAP ($M)1
Unused Revolving Credit Facility Borrowing Capacity ($M)($M)
1,5001,5001,5001,5001,5001,5001,5001,5001,5001,4701,175955
Cash & Cash Equivalents Held Within the United States ($M)($M)1
27873294479569755540920613651.255.838.2
Cash & Cash Equivalents Held by Non-U.S. Subsidiaries ($M)($M)
733737717623687655523316290187182172
Common Stock Repurchased (shares)3
3,643,502971,964673,418703,702523,212418,734314,100306,850221,996231,645260,714335,474
Weighted-Average Price Paid per Repurchased Share ($)($)
232206260249286239239244225216192149
Cumulative Shares Repurchased Since Program Inception (shares)
50,441,54546,798,04345,826,07945,152,66144,448,95943,925,74743,507,01343,192,91342,886,06342,664,06742,432,42242,171,708
Remaining Shares Authorized for Repurchase Under Board Program (shares)
7,917,9708,889,9349,563,35210,267,05410,790,26611,209,00011,523,10011,829,95012,051,94612,283,59112,544,305
Total Inventories, Net ($M)($M)4
1,021946912922946928863882918822830933
Inventories — Finished Goods, Net ($M)($M)
619547559546581558516515542464421463
Inventories — Raw Materials, Net ($M)($M)
398396351375363367343365373356407467
Inventories — Work in Process, Net ($M)($M)
4.102.602122.503.302.602.502.701.802.90
Prepaid Inventory ($M)($M)
31.827.225.123.225.748.266.2104146172197197
Customer Contract Liabilities / Deferred Revenue — Current ($M)($M)3
172163179176168166160157157153151149
Customer Contract Liabilities / Deferred Revenue — Noncurrent ($M)($M)
174171163160159157151147145137132127
Customer Contract Assets — Current ($M)($M)
51.948.747.161.451.151.251.64743.838.237.934.6
Customer Contract Assets — Noncurrent ($M)($M)
13.514.114.214.414.314.614.11515.918.411.110.8
Finite-Lived Intangible Assets, Net ($M)($M)3
443453425430447465430438479486501528
Property, Plant & Equipment, Gross ($M)($M)
1,3601,3331,3461,3121,2871,2561,2331,2141,3251,2751,2571,266
Operating Lease Right-of-Use Assets ($M)($M)3
197153162166162168153151157151147154
Product Warranty Accrual — Current ($M)1
FDA 510(k) Premarket Clearances — ResMed2
131102003001
FDA 510(k) Premarket Clearances — U.S. MedTech Industry Total
855923756806797886736856767793713877
FDA Premarket Approvals (PMA & Supplements) — U.S. MedTech Industry Total
565608567525585588524683538550459656
FDA Medical Device Recall Events — ResMed1
100000000008
FDA Device Enforcement Reports — ResMed
100000000008
FDA MAUDE Adverse Event Reports — ResMed Total4
338215220328270166204252271229248332
ClinicalTrials.gov Newly Started Studies — ResMed
232211221
U.S. Federal Prime Contract Obligations — ResMed Total ($M)($M)
0.000.040.160.030.060.030.200.640.060.660.240.66
U.S. PPI: Electromedical & Electrotherapeutic Apparatus Mfg (Index)(×)4
92.8092.1092.0091.6090.9090.3090.1089.5089.3088.4088.4087.80
Consolidated Net Revenue ($M)($M)10
1,4151,4641,4311,4231,3361,3481,2921,2821,2251,2231,1971,163
Total Assets ($M)($M)15
8,2128,9668,7848,5038,3088,1747,5677,1417,2226,8726,8156,905
Net Cash Provided by Operating Activities ($M)($M)8
422455554340457539579309326440402273

6 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Sleep & Breathing Health Disaggregation (Group 1): Combines Form 10-K/10-Q XBRL disaggregation and Form 8-K Revenue by Product and Region tables across 25 consecutive quarters (Q1 FY2021–Q1 FY2027) and 8 fiscal years (FY2019–FY2026). Starting Q1 FY2027, ResMed further disaggregated Devices into Sleep Devices (CPAP, APAP, and bilevel devices) and Life Support Devices (ventilators) with restated quarterly figures for Q1–Q4 FY2026 across the Americas and Rest of World.
  • Residential Care Software & Portfolio Transformation (Group 2): Tracks Residential Care Software (formerly Software-as-a-Service) revenue, constant-currency growth, business mix, segment operating profit, segment cost of sales, segment R&D, segment SG&A, D&A, and goodwill. On September 1, 2026 (Q1 FY2027), ResMed completed the divestiture of its MatrixCare skilled nursing software business for $490 million ($450.8 million net cash proceeds; $62.2 million pre-tax gain), retaining Brightree (U.S. HME/home health SaaS) and MEDIFOX DAN (German out-of-hospital software).
  • Consolidation Structure Assessment: ResMed Inc. files consolidated U.S. GAAP financial statements in Form 10-K and Form 10-Q without parent-only standalone operational financial statements; accordingly, consolidated minus parent-only subtraction is not applicable. Subsidiary footprint by country is tracked via Form 10-K Exhibit 21.1 and Note 17 geographic disclosures in Group 6.
  • Period Splitting & Derived Figures: Quarterly fourth-quarter (Q4) segment and product revenue figures not separately tabulated in Form 10-K are derived by subtracting nine-month cumulative totals (Form 10-Q for Q3) from full-year totals (Form 10-K), and Q2–Q4 cash flow figures are derived from cumulative year-to-date cash flow statements. No self-calculated ratios, margins, shares, or growth rates are included.

Không hiện vì thiếu các kỳ gần đây (10)

  • 100% Cloud-Connectable Devices in Market ('>31.5M', '>34.5M', '>35.0M', '>37M') — Disclosed solely with lower-bound '>' qualifiers across quarterly presentations and sustainability reports.
  • Patients in AirView Remote Monitoring Ecosystem ('>30M', '>33M', '>35M', '36M+') — Disclosed solely with lower-bound '>' or '+' qualifiers in investor presentations.
  • Patients Registered in myAir Patient Engagement App ('>10M', '>11.0M', '>11.5M', '>12M') — Disclosed solely with lower-bound '>' qualifiers.
  • Cumulative Nights of Sleep & Respiratory Medical Data in Cloud ('>21.5B', '>23.5B', '24.5B+', '25.5B+') — Disclosed solely with lower-bound '>' or '+' qualifiers.
  • Lives Improved in Out-of-Hospital Care ('>149M', '>154M', '>165M', '169M+') and Countries Served ('140+') — Disclosed solely as lower-bound figures.
  • Global Sleep Devices & Global Life Support Devices Standalone Revenue ($716M / $4M in Q1 FY2027; $655M / $25M in Q1 FY2026) — Global totals disclosed for only 2 quarters (Q1 FY2026 and Q1 FY2027) without Q2–Q4 FY2026 global subtotals, whereas Americas and Rest of World Sleep Devices and Life Support Devices have all 5 consecutive quarters (Q1 FY2026–Q1 FY2027) plus FY2026 full year and are included in Group 1.
  • Americas Masks and Other & Total Americas Sleep and Breathing Health Core Constant Currency Growth (10% and 7% in Q1 FY2027) — Disclosed for only 1 quarter (Q1 FY2027) following the Noctrix acquisition adjustment; prior Form 8-K tables reported only GAAP YoY growth for the Americas.
  • EU Public Country-by-Country Report (CbCR) Country Breakdown (Germany $343.4M / 1,306 employees, France $303.8M / 392 employees, Netherlands $785.1M, Ireland $181.3M, Italy $53.1M, Finland $44.1M) — Published for a single fiscal year (FY2025) under EU Directive 2021/2101 (<2 consecutive years).
  • Tier I Direct Supplier Code of Conduct & Environmental/Safety Assessment Rate ('95+%' in FY2023–FY2026 Sustainability Reports) — Disclosed solely as a lower-bound percentage ('95+%').
  • Total Recordable Injury Frequency Rate (TRIFR: 4.19 in FY2021, 3.31 in FY2022, 3.09 in FY2023) and Lost Time Injury Frequency Rate (LTIFR: 1.71, 1.89, 1.98) — Discontinued in the FY2025 and FY2026 Sustainability Data Tables.

Dữ liệu cập nhật 2026-11-08.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của ResMed

See a number that looks wrong?